NervGen Pharma Corp. Common stock (NGEN) Stock Price
NGENStock
$2.28−2.04%52W
Market Cap$245.15M
P/E—
PEG Ratio—
Div yield—
Beta1.45
NGEN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)36.69%
Price vs S&P 500 (4W)-5.18%
VGM Score47.10
NGEN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.05 | -$0.17 | -245.68%(-$0.12) | |
| Q1 2026 | -$0.04 | -$0.05 | -11.79%(-$0.01) | |
| Q4 2025 | -$0.05 | -$0.19 | -284.16%(-$0.14) |
NGEN Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NGENNervGen Pharma Corp. Common stock | — | — | C | $2.28 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About NervGen Pharma Corp. Common stock
NervGen Pharma is a clinical-stage biotech company developing therapies to enable the nervous system to repair itself following injury or disease. The company's initial focus is spinal cord injury, with lead candidates NVG-291 and NVG-300 in its pipeline.